FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials

This Perspective discusses the draft guidance for industry that the US Food and Drug Administration released on the use of bayesian methods in testing therapeutics.

Authors

Witold Więcek (ORCID: https://orcid.org/0000-0003-3016-1449)
Andrew Gelman
Erik van Zwet

Institutions

Leiden University Medical Center (NL)
University of Illinois Chicago (US)
University of Chicago (US)
Columbia University (US)

Publication Details

Journal: JAMA
Published: 2026-03-23
DOI: https://doi.org/10.1001/jama.2026.4178
Primary Topic: Statistical Methods in Clinical Trials
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials

Witold Więcek, Andrew Gelman, Erik van Zwet

Mar 23, 2026

JAMA

Statistical Methods in Clinical Trials

article

FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials

Witold Więcek, Andrew Gelman, Erik van Zwet

March 23, 2026article en

Abstract

This Perspective discusses the draft guidance for industry that the US Food and Drug Administration released on the use of bayesian methods in testing therapeutics.

JAMA

Leiden University Medical Center (NL), University of Illinois Chicago (US), University of Chicago (US), Columbia University (US)

Zero hunger

Openalex Percentile: Top 17%

Statistical Methods in Clinical Trials

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.